Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/15/2019 07/16/2019 07/17/2019 07/18/2019 07/19/2019 Date
134.71(c) 132.5(c) 131.86(c) 132.07(c) 130.31(c) Last
10 038 224 10 214 538 8 862 093 6 203 739 7 676 702 Volume
+0.31% -1.64% -0.48% +0.16% -1.33% Change
More quotes
Financials (USD)
Sales 2019 81 594 M
EBIT 2019 25 389 M
Net income 2019 18 319 M
Debt 2019 6 116 M
Yield 2019 2,87%
Sales 2020 85 081 M
EBIT 2020 27 984 M
Net income 2020 20 896 M
Finance 2020 1 535 M
Yield 2020 3,06%
P/E ratio 2019 19,4x
P/E ratio 2020 17,2x
EV / Sales2019 4,32x
EV / Sales2020 4,05x
Capitalization 346 B
More Financials
Company
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (49.9%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses,... 
Sector
Pharmaceuticals
Calendar
10/15 | 06:45amEarnings Release
More about the company
Surperformance© ratings of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
Latest news on JOHNSON & JOHNSON
07/19JOHNSON & JOHNSON INVESTIGATION UPDA : Kahn Swick & Foti, LLC Continues to Inves..
BU
07/19JOHNSON & JOHNSON : J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in M..
DJ
07/18JOHNSON & JOHNSON : Oklahoma County seeking lawsuit against opioid manufacturers
AQ
07/18JOHNSON & JOHNSON : DRC rejects clinical trial for experimental Ebola vaccine
AQ
07/17JOHNSON & JOHNSON : Extends Long-Standing Donation Program to Support Global Eff..
AQ
07/17GENMAB : Announces Net Sales of DARZALEX for Second Quarter of 2019
AQ
07/17JOHNSON & JOHNSON : 's Baltic net profits down 42% to EUR 1.2 million
AQ
07/17J&J Lifts Forecast As Suits Weigh On Its Shares -- WSJ
DJ
07/17JOHNSON & JOHNSON : Pharma strength boosts Johnson & Johnson profit
AQ
07/16Wall Street slips as bank earnings, Trump trade comments weigh
RE
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Sector news : Pharmaceuticals - NEC
07/19CELGENE : Says FDA Approves Otezla for Oral Ulcers in Behcet's Disease
DJ
07/19ALLERGAN : Form 8.3 -
DJ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/19BAYER : Syngenta profits hit by U.S./China trade wars, bad weather
RE
07/19BAYER : welcomes judge's call for reduced damages in $2 billion glyphosate case
RE
More sector news : Pharmaceuticals - NEC
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 149,00  $
Last Close Price 130,31  $
Spread / Highest target 29,7%
Spread / Average Target 14,3%
Spread / Lowest Target -4,84%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.34%345 980
PFIZER-1.35%237 451
ROCHE HOLDING LTD.11.42%230 263
ROCHE HOLDING13.37%230 263
NOVARTIS24.46%216 273
MERCK AND COMPANY6.52%209 550